首页> 外国专利> UNIONS AND METHODS FOR THE DISPOSAL OF MEDICINAL PRODUCTS NECESSARY TO THE MARKETING AUTHORISATION OF MEDICINAL PRODUCTS OR WASTE MATERIALS PROVISIONS OF THE FRENCH SELF

UNIONS AND METHODS FOR THE DISPOSAL OF MEDICINAL PRODUCTS NECESSARY TO THE MARKETING AUTHORISATION OF MEDICINAL PRODUCTS OR WASTE MATERIALS PROVISIONS OF THE FRENCH SELF

机译:法国自我的药品或废料规定的营销授权所需的药品的联合和处理方法

摘要

This disclosure is focused on compounds and methods for the treatment of fluid retention or salt overload -related disorders,such as heart failure (in particular,congestive heart failure),chronic kidney disease,end stage renal disease,Hepatic disease and fluid retention induced by a c -agonist activated hyperacidosis multiplier (PPAR) receptor. This revelation is directed at:in compounds and methods for the treatment of hypertension. This disclosure is also focused on compounds and methods for the treatment of gastrointestinal disorders.including treatment or reduction of pain associated with gastrointestinal disorders. Methods generally include administrationor in a mammal in need of a pharmacologically effective amount of a compound or a pharmaceutical formulation containing such a compoundDesigned to be essentially gastrointestinal (GI) active to inhibit neo -mediated sodium ions and virus antibody of hydrogen in it. Specifically,the method includes the administration to a mammal in need of a pharmacologically effective amount of a compound or a pharmaceutical formulation that: includes such a union,which inhibits the transfer of sodium and /or hydrogen ions into the GI gastrointestinal tract by NEE -3, -2 and / or -8 -mediated transfer of sodium and /or hydrogen ions and is designed to be a substance seemingly impermeable to the epithelial cell layer,or more specifically than the epithelium of the GI gastrointestinal tract. As a result of the substance which is essentially impenetrable,is not absorbed and is therefore essentially systematically unavailable,so as to limit the exposure of other internal bodies (e.g. of the liver,of the heart,the brain etc.) on it. This revelation is still focused on one method,where such a compound is administered to a mammal with a liquid absorption polymer,so that the combination acts as described above and additionally provides the ability to isolate the liquid and /or salt present in the stomach GI tube.
机译:本公开内容集中于用于治疗与体液retention留或盐超载相关的疾病,例如心力衰竭(特别是充血性心力衰竭),慢性肾脏病,末期肾病,肝病和由其引起的体液retention留的化合物和方法ac激动剂激活的高酸中毒乘数(PPAR)受体。该启示针对:用于治疗高血压的化合物和方法。本公开内容还集中于用于治疗胃肠道疾病的化合物和方法,包括治疗或减轻与胃肠道疾病有关的疼痛。方法通常包括在需要药理学有效量的化合物或含有这种化合物的药物制剂的哺乳动物中给药,所述化合物或设计成对胃肠道(GI)基本上具有抑制新介导的钠离子和其中的氢的病毒抗体活性的胃肠道。具体而言,该方法包括向需要药物有效量的化合物或药物制剂的哺乳动物给药:包括这样的结合,该结合或结合抑制钠和/或氢离子通过NEE转移到胃肠道中- 3,-2和/或-8介导的钠和/或氢离子的转移,被设计为表面上层细胞层(或更具体而言比GI胃肠道上皮)不可渗透的物质。由于该物质基本上是不可渗透的,未被吸收,因此基本上是系统上无法获得的,从而限制了其他内部物体(例如肝脏,心脏,大脑等)的暴露。该启示仍然集中在一种方法上,其中将这种化合物与液体吸收聚合物一起施用给哺乳动物,以使该组合物如上所述发挥作用,并且还提供了分离存在于胃肠道中的液体和/或盐的能力。管。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号